Latest news with #Bristol-MyersSquibb
Yahoo
a day ago
- Business
- Yahoo
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug
Bristol-Myers Squibb (NYSE:BMY) is doubling down on its oncology ambitions with a deal that could reach $11.1 billion, partnering with BioNTech (NASDAQ:BNTX) to co-develop a next-generation cancer therapy known as BNT327. The German biotech will receive $1.5 billion upfront, $2 billion in staggered payments through 2028, and stands to gain another $7.6 billion if clinical and commercial milestones are met. Both companies will share development costs and future profits. The deal reflects growing urgency among pharma giants to replenish their pipelines, as legacy blockbusters face generic competition. Bloomberg Intelligence estimates this class of immunotherapy drugs could generate $60 billion annually by 2027. BNT327's backstory adds intrigue. BioNTech originally licensed the compound from Chinese biotech Biotheus in 2023 before acquiring the company outright for up to $950 million. It's now positioning the therapy as a core asset in its oncology portfolio. While early trial data suggests Pfizer's competing drug may show stronger efficacy, BioNTech is further along in developing broader cancer indications. The approach behind these drugs is evolving fastmerging immunotherapy with anti-angiogenesis mechanisms to cut off tumors' blood and oxygen supply. This model gained traction after Akeso and Summit Therapeutics' combination therapy showed promising results against Merck's Keytruda in a major Chinese trial. Still, the bar remains high. These new therapies haven't yet demonstrated a consistent survival advantage over standard treatments, and head-to-head data outside China could take years. For BioNTech, though, this deal marks a decisive return to its original focuscancerafter riding a pandemic-era wave with its COVID-19 vaccine. Bristol-Myers also gains optionality: the ability to pair BNT327 with other in-house experimental compounds. With both firms now locked into a shared bet on combo therapies, this could be a pivotal move in a rapidly shifting oncology landscape. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Cancer Moonshot: Bristol-Myers Just Dropped $11 Billion on a Single BioNTech Drug
Bristol-Myers Squibb (NYSE:BMY) is doubling down on its oncology ambitions with a deal that could reach $11.1 billion, partnering with BioNTech (NASDAQ:BNTX) to co-develop a next-generation cancer therapy known as BNT327. The German biotech will receive $1.5 billion upfront, $2 billion in staggered payments through 2028, and stands to gain another $7.6 billion if clinical and commercial milestones are met. Both companies will share development costs and future profits. The deal reflects growing urgency among pharma giants to replenish their pipelines, as legacy blockbusters face generic competition. Bloomberg Intelligence estimates this class of immunotherapy drugs could generate $60 billion annually by 2027. BNT327's backstory adds intrigue. BioNTech originally licensed the compound from Chinese biotech Biotheus in 2023 before acquiring the company outright for up to $950 million. It's now positioning the therapy as a core asset in its oncology portfolio. While early trial data suggests Pfizer's competing drug may show stronger efficacy, BioNTech is further along in developing broader cancer indications. The approach behind these drugs is evolving fastmerging immunotherapy with anti-angiogenesis mechanisms to cut off tumors' blood and oxygen supply. This model gained traction after Akeso and Summit Therapeutics' combination therapy showed promising results against Merck's Keytruda in a major Chinese trial. Still, the bar remains high. These new therapies haven't yet demonstrated a consistent survival advantage over standard treatments, and head-to-head data outside China could take years. For BioNTech, though, this deal marks a decisive return to its original focuscancerafter riding a pandemic-era wave with its COVID-19 vaccine. Bristol-Myers also gains optionality: the ability to pair BNT327 with other in-house experimental compounds. With both firms now locked into a shared bet on combo therapies, this could be a pivotal move in a rapidly shifting oncology landscape. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Bristol-Myers Squibb (BMY)
Analysts fell to the sidelines weighing in on Arvinas Holding Company (ARVN – Research Report) and Bristol-Myers Squibb (BMY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Arvinas Holding Company (ARVN) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company yesterday. The company's shares closed last Friday at $7.20. According to Biegler 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arvinas Holding Company with a $14.66 average price target, implying a 95.5% upside from current levels. In a report released yesterday, Leerink Partners also downgraded the stock to Hold with a $9.00 price target. Bristol-Myers Squibb (BMY) Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb on May 31. The company's shares closed last Friday at $48.28. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co. The word on The Street in general, suggests a Hold analyst consensus rating for Bristol-Myers Squibb with a $55.53 average price target, representing a 16.0% upside. In a report issued on May 16, BMO Capital also maintained a Hold rating on the stock with a $53.00 price target.
Yahoo
3 days ago
- Business
- Yahoo
A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the lesson grounded in practicality, we'll use ROE to better understand Bristol-Myers Squibb Company (NYSE:BMY). Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Bristol-Myers Squibb is: 31% = US$5.4b ÷ US$17b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.31. Check out our latest analysis for Bristol-Myers Squibb Arguably the easiest way to assess company's ROE is to compare it with the average in its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. As you can see in the graphic below, Bristol-Myers Squibb has a higher ROE than the average (19%) in the Pharmaceuticals industry. That's what we like to see. However, bear in mind that a high ROE doesn't necessarily indicate efficient profit generation. A higher proportion of debt in a company's capital structure may also result in a high ROE, where the high debt levels could be a huge risk . You can see the 3 risks we have identified for Bristol-Myers Squibb by visiting our risks dashboard for free on our platform here. Companies usually need to invest money to grow their profits. The cash for investment can come from prior year profits (retained earnings), issuing new shares, or borrowing. In the case of the first and second options, the ROE will reflect this use of cash, for growth. In the latter case, the debt used for growth will improve returns, but won't affect the total equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same. Bristol-Myers Squibb clearly uses a high amount of debt to boost returns, as it has a debt to equity ratio of 2.85. While no doubt that its ROE is impressive, we would have been even more impressed had the company achieved this with lower debt. Debt does bring extra risk, so it's only really worthwhile when a company generates some decent returns from it. Return on equity is a useful indicator of the ability of a business to generate profits and return them to shareholders. A company that can achieve a high return on equity without debt could be considered a high quality business. All else being equal, a higher ROE is better. But ROE is just one piece of a bigger puzzle, since high quality businesses often trade on high multiples of earnings. It is important to consider other factors, such as future profit growth -- and how much investment is required going forward. So I think it may be worth checking this free report on analyst forecasts for the company. But note: Bristol-Myers Squibb may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Vitiligo Market Growth Trends and Forecast Report 2025-2033 - Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access
Global Vitiligo Market to hit USD 1.09 billion by 2033, driven by increased awareness and advancements in treatment. With a CAGR of 5.53% from 2025 to 2033, demand grows for innovative therapies, bolstered by rising healthcare access and investment. Key players include Incyte, Pfizer, and Bristol-Myers Squibb. Vitiligo Market Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to rise in prevalence of autoimmune skin diseases, the growth of dermatological treatments, and improving knowledge about vitiligo are driving the market to grow steadily during the forecast period. North America holds a major share due to high awareness and advanced healthcare systems, while Asia-Pacific is expected to see rapid growth driven by increasing medical investments and awareness initiatives. Each segment contributes uniquely to the dynamics of the vitiligo market, offering diverse opportunities for stakeholders across pharmaceutical and service-based Awareness and Early DiagnosisIncreasing awareness campaigns and education programs by healthcare institutions have contributed to better knowledge and early detection of vitiligo. Patient support groups and social media also help in de-stigmatizing the disease, and more individuals are seeking medical help. Demand for over-the-counter and prescription products is being driven by this awareness. Furthermore, improvements in diagnostic technology are making it possible for dermatologists to detect vitiligo earlier, which facilitates more effective treatments. All of these factors collectively are greatly increasing the size of the market and inducing investment in novel therapies. June 2024, Glenmark Pharmaceuticals Ltd and the IADVL initiated a campaign for awareness about vitiligo, a skin disease related to pigmentation. The effort involves postcards and a calendar with paintings of a painting contest on World Vitiligo Day to raise awareness and treatment options for the in Treatment ModalitiesNew research and advances in dermatology have brought unprecedented developments in vitiligo treatments. Some advances include topical JAK inhibitors, enhanced phototherapy equipment, and regenerative methods through melanocyte transplantation. These innovations are enhancing patient satisfaction and outcomes, driving demand for advanced care. Pharmaceutical companies and biotech companies are investing more in clinical trials for new medicines, with the goal of providing more targeted and longer-lasting treatments. This increase in innovation is propelling the growth of the global market for vitiligo treatment by offering more effective and convenient treatments. October 2024, Kenvue Inc, the consumer health leader, has unveiled multi-year collaborations for its Neutrogena brand with world-renowned skincare expert Dr. Dhaval Bhanusali and the world's most followed dermatologist, Dr. Muneeb Healthcare Spending and AccessRising healthcare spending worldwide, particularly in developing economies, is facilitating greater access to dermatological treatment and advanced vitiligo therapies. Government-funded health initiatives and increased insurance coverage are making patients able to pay for both light-based and topical treatments. Additionally, the increase in teledermatology platforms is enhancing specialist access, especially in rural and underserved areas. With increased affordability and infrastructure, patients are now more willing to receive treatment, leading to the overall market growth and providing new opportunities for service providers and drug in the Global Vitiligo Market Limited Treatment Effectiveness and Risk of RecurrenceNotwithstanding the progress, most treatments for vitiligo are limited in long-term effectiveness and have high rates of recurrence. Permanent or complete repigmentation is unattainable for most patients. Topical interventions can take several months to manifest and are not equally effective in all skin types or stages of vitiligo. Light therapy, though successful in some cases, also has the risk of skin damage and patchy pigmentation. These challenges inhibit long-term compliance among patients and decrease total satisfaction with treatment, presenting a critical hindrance to market development and and Social Stigma BarriersVitiligo is widely stigmatized in most societies, preventing patients from going for diagnosis or treatment. The social stigma is likely to cause emotional trauma, worry, and depression, which ultimately lead to treatment default. Vitiligo has, in certain regions, been incorrectly believed to be infectious or connected to other illness, heightening segregation. Psychological barriers are key in treatment access and patient participation. Until stigma is tackled through public health advocacy and education, the market will fail to reach its full potential, especially in conservative or underserved areas. Key Players Analyzed: Overview, Key Persons, Recent Developments, Product Portfolio, Revenue Incyte Corporation Bristol-Myers Squibb Clinuvel Pharmaceuticals Ltd Astellas pharma inc Baxter International Inc. Pfizer Dr. Reddy's Laboratories Ltd Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $674 Million Forecasted Market Value (USD) by 2033 $1090 Million Compound Annual Growth Rate 5.5% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Vitiligo Patient Numbers & Market5.1 Vitiligo Market5.2 Vitiligo Patients (Thousand)6. Global Vitiligo Patient Numbers & Market Share Analysis6.1 Market Share6.1.1 By Vitiligo Type6.1.2 By Treatment Type6.1.3 By End User6.1.4 By Country Vitiligo Market Share6.2 Volume Share6.2.1 By Country Vitiligo Patient Numbers Share7. Diseases Type7.1 Segmental7.2 Non Segmental8. Treatment Type8.1 Topical Treatments8.2 Light Therapy8.3 Surgical Procedures8.4 Others9. End User9.1 Hospitals9.2 Ambulatory Clinics9.3 Others10. Country10.1 United States10.1.1 Vitiligo Market10.1.2 Vitiligo Patient (Thousand)10.2 Canada10.3 Mexico10.4 Germany10.5 United Kingdom10.6 France10.7 Italy10.8 Spain10.9 Japan10.10 China10.11 Australia10.12 India10.13 Brazil10.14 Saudi Arabia10.15 Argentina10.16 United Arab Emirates10.17 South Africa10.18 Rest of World11. Clinical Study of Vitiligo Market12. Porter's Five Forces12.1 Bargaining Power of Buyer12.2 Bargaining Power of Supplier12.3 Threat of New Entrants12.4 Rivalry among Existing Competitors12.5 Threat of Substitute Products13. SWOT Analysis13.1 Strengths13.2 Weaknesses13.3 Opportunities13.4 Threats14. Company Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Vitiligo Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
